To inspire and empower millions of people living with Parkinson’s around the world, Bial launches a touching campaign for the World Parkinson’s Day showing that it is possible to live a normal life, and successfully perform everyday tasks
Imagine being unable to control your own body. In your mind, everything is exactly like it was; but your brain seems to have forgotten how to tell your body to do everyday tasks like tying up shoes or using a toothbrush.
This is how it feels to live with Parkinson’s. A real challenge for the 10 million people diagnosed with Parkinson’s around the world. Parkinson’s is a progressive neurodegenerative disease – an illness that affects nerve cells in the brain. For those who live with these symptoms and for their families, Parkinson’s means much more than just physical symptoms: it also means a loss of their independence.
In order to raise awareness and help people keep their self-esteem, people with Parkinson’s were invited to star in a video that shows them at their best by focusing on what they can do instead of what they cannot do. Buttoning up shirts, putting on make-up, tying up shoes or even dancing and playing musical instruments. Simple, everyday tasks alongside a cheerful, feel-good tune developed specially for the campaign.
António Portela, CEO of Bial, explains the positive tone of the campaign: “Parkinson’s can really change people’s lives, but it’s very important that they do not lose their self-esteem. That is why we wanted to counter the negative portraits of people with Parkinson’s and show everyone what they really can do. Hopefully, we can inspire and empower the millions of people living with Parkinson’s to never give up on their dignity. Bial’s aim is to help the lives of people with Parkinson’s even if it’s to help with one small thing at a time.”
The campaign launches worldwide today – on World Parkinson’s Day – and is featured on Bial’s website, across Bial’s social media and on the European Parkinson’s Disease Association’s social media channels too.
Watch the video ‘Me at my best’ below
This article is sponsored by Bial. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Founded in 1924, Bial’s mission is to discover, develop and provide therapeutic solutions within the area of health. In recent decades, Bial has strategically focused on quality, innovation and internationalisation. Bial has channelled more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system.
In 2016 Bial launched Opicapone for Parkinson’s disease. Already available in Germany and in the United Kingdom, it will be introduced in the remaining European countries throughout 2017.
Currently representing around two thirds of its turnover, Bial will continue to strengthen its international presence based in its own innovative medicines, particularly in the most important European pharmaceutical markets, Spain, Germany, United Kingdom and Italy, where the company is already present with its own affiliates. For more information about Bial, please visit www.bial.com.
Standing tall: the fashion blogger and young onset campaigner who’s back in heels (thanks to DBS)
Tonya Walker, fashion blogger and young onset Parkinson's campaigner
5 hours ago
Sniff test could detect Parkinson’s disease up to a decade earlier
A study has found that white adults with a poor sense of smell are almost five times more likely to develop Parkinson’s disease than those with a stronger smell sense. The research, published in the medical journal ‘Neurology’, found that there was not a statistically significant link between Parkinson’s and smell for black adults. Speculating on the reaction that people from different racial backgrounds had to the test, researchers said: “One possibility is that, compared to white participants, the etiology of olfactory dysfunction in black participants is more diverse and complex, and that Parkinson’s disease-related pathology is a relatively minor contributor.” The team emphasised that the findings should be interpreted with caution – and that further studies are needed before the smell tests can reach a clinical stage.
Spiral drawing test could detect early signs of Parkinson’s
Researchers from RMIT University, Australia, have developed a test that may be able to detect early Parkinson’s – before physical symptoms appear. During the test, participants draw a spiral using a tablet device, and computer software then measures their drawing speed and pen pressure to diagnose the condition. PhD researcher Poonam Zham led the study, published in ‘Frontiers of Neurology’, with the RMIT biomedical engineering research team. Working with Dandenong Neurology, the study involved 62 people diagnosed with Parkinson’s. Half had no visible symptoms and half ranged from mildly- to severely-affected. Professor Dinesh Kumar, chief investigator, said: “The customised software we’ve developed records how a person draws a spiral and analyses the data in real time. “With this tool we can tell whether someone has Parkinson’s disease and calculate the severity of their condition, with a 93% accuracy rate.” Image credit: RMIT University – Professor Dinesh Kumar and Poonam Zham
Asthma drug could halve chance of developing Parkinson’s
A recent study has found that a drug most commonly used for asthma may cut the chances of developing Parkinson’s. The research, carried out by Harvard Medical School, Massachusetts, US, found that those who inhaled salbutamol – a drug found in inhalers – were half as likely to develop the condition. In Parkinson’s disease, a protein named a-synuclein accumulates in various brain cells and can be fatal. To counter this, the research team grew human nerve cells and tested over 1000 medications, finding results to suggest salbutamol could cut the production of a-synuclein. Neurologist Anthony Lang, who works at the University of Toronto, Canada, said the results were “fascinating” and “had come out of the blue”. Despite some encouraging developments, Clemens Scherzer, who was a part of the research team, said clinical trials were “a few years off”.